

## **AMENDMENTS TO THE SPECIFICATION**

In the specification, at page 1, after the heading 'Background of the Invention', please delete the existing paragraph pertaining to 'Cross-reference to Related Applications' and replace the deleted paragraph with the following paragraph after implementing the indicated changes:

The present application is a divisional of co-pending U.S. patent application Serial No. 09/561,005, filed April 28, 2000, which claims priority to ~~co-pending~~ U.S. provisional patent application Serial No. 60/131,432, filed April 28, 1999, the entire text and drawings of which ~~application is~~ applications are specifically incorporated by reference herein without disclaimer. The U.S. Government owns rights in the present invention pursuant to grant numbers 1RO1 CA74951, 5RO CA54168 and T32 GM07062 from the National Institutes of Health.

In the specification, at page 119, lines 1-8, please delete the existing paragraph and replace the deleted paragraph with the following replacement paragraph after implementing the indicated changes:

The following patents and patent applications are specifically incorporated herein by reference for the purposes of even further supplementing the present teachings regarding the preparation and use of functional, antigen-binding regions of antibodies, including scFv, Fv, Fab', Fab and F(ab')<sub>2</sub> fragments of the anti-VEGF antibodies: U.S. Patent No. 5,855,866; 5,965,132; 6,051,230; 6,004,555; and 5,877,289; and ~~U.S. Application Serial No. 08/482,369, Issue Fee Paid October 20, 1998~~ 6,093,399. WO 98/45331 is also incorporated herein by reference for purposes including even further describing and teaching the preparation of variable, hypervariable and complementarity determining (CDR) regions of antibodies, ~~including~~ \_\_\_\_\_.

In the specification, at page 120, lines 7-15, please delete the existing paragraph and replace the deleted paragraph with the following replacement paragraph after implementing the indicated changes:

Moderate conjugation-type modifications for use with the present invention include incorporating a salvage receptor binding epitope into the antibody fragment. Techniques for achieving this include mutation of the appropriate region of the antibody fragment or incorporating the epitope as a peptide tag that is attached to the antibody fragment. WO 96/32478 is specifically incorporated herein by reference for the purposes of further exemplifying such technology. Salvage receptor binding epitopes are typically regions of three or more amino acids from one or two ~~lops~~ loops of the Fc domain that are transferred to the analogous position on the antibody fragment. The salvage receptor binding epitopes of WO 98/45331 are incorporated herein by reference for use with the present invention.